Business Wire

Energy Dome Closes 40 Million Euro Series B Financing Round

Share

Energy Dome, the company behind the CO2 Battery™, the innovative long-duration energy storage solution, today announced it has closed a 40 million euro (circa $44 million) Series B funding round.

The financing round was led by Eni Next, the corporate venture capital arm of Eni. Eni Next invests in high-growth start-ups to boost the energy transition to a zero-carbon future. Its portfolio includes start-ups with the most disruptive technologies, such as energy storage and fusion. The round was co-led by Neva SGR, the venture capital company of Intesa Sanpaolo, one of Europe’s largest banking groups. Climate tech and energy transition technologies are among the key areas of the investment strategy for Neva SGR.

Existing investors have followed Energy Dome’s Series B round, confirming their belief in the potential of the company and the team behind it, including Barclays’ Sustainable Impact Capital, CDP Venture Capital, Italian asset management company owned by CDP Equity Spa, and Invitalia, with the aim of fostering the development of all players in the innovation ecosystem via its Evolution Fund, Novum Capital Partners, a Swiss multi-family office via its investors, and 360 Capital, a Paris- and Milan-based VC with the utility A2A as one of the main limited partners. Also joining the round is Japan Energy Fund, a specialized climate tech venture fund representing entities including Biprogy, Enechange, Mitsui Sumitomo Trust Bank and Toshiba Energy Systems. Participants in the Series B include Elemental Excelerator, a U.S. nonprofit investor focused on climate tech.

This financing round brings invested-in capital in Energy Dome to some 54 million euros. Proceeds from this investment will enable Energy Dome to enter full commercial scaling mode on a global basis.

After the successful closing, Claudio Spadacini, Energy Dome’s Founder and CEO, shared his message to the market: “Imagine a system that can store renewable energy with 75% RTE (AC-AC, MV-MV) and a cost which is half the cost of lithium. A system that has no degradation over 30 years and that is made of just steel, water and CO2. Now imagine that that system is made of existing and well-known components that any power plant operator is capable of maintaining and operating, and those components are deployable at GWh scale globally with no bottlenecks on the supply chain or specific site constraints. If you like this idea, stop imagining. Because this is reality, the technology is sorted. Our CO2 Battery™ is ready for the market and, after closing the Series B round, we are ready to guarantee its performance to any customer that is real about getting rid of fossil fuels and substituting with dispatchable renewable energies.”

Energy Dome’s solution for long-duration energy storage is achieving an enthusiastic reception in the global marketplace. Energy Dome is already working with several utilities, independent power producers and corporate customers in key markets, resulting in a qualified pipeline that exceeds 9GWh in markets such as the U.S., Europe, South America, India and Australia. The Company’s short-term objective is to keep up the momentum gained so far; Energy Dome went from start of operation to full commercial-scale deployment in just three years and will have two standard 20MW-200MWh frames commercially operational by the end of 2024. The first unit is already under manufacturing, with the longest leading items being manufactured by key suppliers.

More About the Round

With participation from well-capitalized international investors, this Series B round will enable further commercialization of Energy Dome’s technology around the world and will support the expansion of Energy Dome’s team in key markets, with a specific focus on the U.S.

The use of proceeds of the round will serve to provide financial guarantees to customers as a demonstration that this team is ready to put their “skin in the game” alongside their customers in deploying the CO2 Battery™. The investment will also support Energy Dome’s business expansion in the U.S. in order to leverage at maximum from the opportunities deriving from the Inflation Reduction Act and the associated Investment Tax Credits available for utility-scale energy storage.

About Energy Dome

Energy Dome is revolutionizing energy storage and enabling grid decarbonization by making solar and wind power dispatchable 24/7. The company invented and developed the CO2 Battery™, a long-duration energy storage system that makes long-duration energy storage viable globally today. The properties of carbon dioxide allow the system to store energy efficiently and cost-effectively, with a modular and site-independent footprint. CO2 Batteries™ use readily available, off-the-shelf components from reliable, existing supply chains, providing a pathway to store massive amounts of intermittent renewable energy and accelerate the energy transition. For more information, please visit www.energydome.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Brent Shelton
PRforEnergyDome@bospar.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 01:49:00 EET | Press release

Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye